

Harvest One Cannabis Inc

12:05 13 Aug 2019

Buds & Duds: Cannabis stocks on the rise Tuesday; Harvest One shares jump on promising epilepsy trial results

Cannabis stocks perked up on Tuesday, with broad-based gains across North American markets.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, gained 2% at 210.3 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF gained 1.25% to C\$17.03, while the OTCQX Cannabis Index was up 1.9% to 699 points.

Buds

Harvest One Cannabis Inc (CVE:HVT) (OTCMKTS:HRVOF) shares were on the rise Tuesday after the firm announced its Satipharm Ltd subsidiary saw strong results from a clinical trial of its CBD GelPell capsules to treat children with epilepsy.

Shares of Harvest One were up 3.5% at C\$0.59 in Toronto, and up 5.4% at US\$0.44 in New York.

The Phase 2 trial of children with treatment-resistant epilepsy found a median monthly seizure reduction of 82% over the 12-week treatment period when GelPell was added to patients' current medications. More than half of the patients who started treatment saw a reduction in seizure frequency of at least 50%, and two patients were seizure-free within five weeks.

READ: Harvest One subsidiary Satipharm's CBD capsules shown to reduce seizures in Phase 2 pediatric epilepsy trial

Also on the rise Tuesday was The Supreme Cannabis Company Inc (TSE:FIRE) (OTCMKTS:SPRWF), after it boosted its fourth-quarter expectations, anticipating about \$19 million for 4Q. Forecasts for net revenue in fiscal 2020 came in between \$150 million and \$180 million.

Shares were on the rise, up 10.5% at US\$1.05, and in New York, up 12.1% at C\$1.39.

"Our company has taken deliberate steps to grow in a focused, responsible and compliant manner, building a strong core business and an authentic brand and then expanding into new lines of business and international markets," said Navdeep Dhaliwal, CEO of Supreme Cannabis.

Duds


Laggards Tuesday included MariMed Inc (OTCMKTS:MRMD), despite posting record 2Q financial results. Its shares were down 1.2% at US\$1.65.

The firm reported a 774.0% rise in revenue to US\$25.7 million in 2Q. Net income came in at US\$4.7 million, improving from a net loss of US\$393,000 in the year-ago period.

Price: C\$0.58

Market Cap: C\$118071000M

1 Year Share Price Graph



August 2018 February 2019 August 2019

Share Information

Code: HVT

Listing: TSX-V

52 week High Low
C\$1.15 C\$0.33

Sector: Cannabis [T3]

Website: www.harvestone.com

Company Synopsis:

Harvest One is a global cannabis company that develops and provides innovative lifestyle and wellness products to consumers and patients in regulated markets around the world. The Company's range of lifestyle solutions is designed to enhance quality of life.

action@proactiveinvestors.com

"The second quarter of this year marks a milestone," said MariMed president and CEO, Bob Fireman. "Both of our business divisions—cannabis and hemp—delivered this quarter to drive record results."

Also lagging Tuesday was CannTrust Holdings Inc (TSE:TRST) (NYSE:CTST), which continued to slide after the company announced Monday that Health Canada had found a second of its facilities was "non-compliant with certain regulations."

Shares dropped 2.6% to C\$2.96 in Toronto, and were down 3.2% at US\$2.24 in New York.

CannTrust has been embroiled in a scandal since early July after Health Canada found it was growing cannabis in unlicensed rooms at its Vaughan, Ontario facility.

According to a company release Monday, the firm noted Health Canada has flagged the company for improper cannabis storage procedures, inadequate quality assurance, failing to retain documents and inadequate security protocols at a second facility, also located in Vaughan, Ontario.

-- Harriet Mclelland contributed to this report --

Contact Katie Lewis at katie@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.